Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: A review

Journal of Urology

Volumn 169, Issue 6, 2003, Pages 2352-2359

  Pruthi, Raj S ^a   Derksen, Eric ^a   Gaston, Kris ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bladder neoplasms; Cyclooxygenase inhibitors; Kidney neoplasms; Prostaglandins; Prostatic neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN;

ANGIOGENESIS; APOPTOSIS; BLADDER TUMOR; CANCER GROWTH; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; IMMUNE DEFICIENCY; KIDNEY TUMOR; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE TUMOR; REVIEW; UROGENITAL TRACT TUMOR;

EID: 0038625360     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000047364.56051.74     Document Type: Review

References (70)

1. Vane, J. R.: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 231: 232, 1971
2. Futaki, N., Takahashi, S., Yokoyama, M., Arai, I., Higuchi, S. and Otomo, S.: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins, 47: 55, 1994
3. Fosslien, E.: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci, 30: 3, 2000
4. Turini, M. E. and DuBois, R. N.: Cyclooxygenase-2: a therapeutic target. Annu Rev Med, 53: 35, 2002
5. Appleby, S. B., Ristimaki, A., Neilson, K., Narko, K. and Hla, T.: Structure of the human cyclo-oxygenase-2 gene. Biochem J, 302: 723, 1994
6. Almer, G., Guegan, C., Teismann, P., Naini, A., Rosoklija, G., Hays, A. P. et al: Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol, 49: 176, 2001
7. Halliday, G., Robinson, S. R., Shepherd, C. and Kril, J.: Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol, 27: 1, 2000
8. Castrop, H., Schweda, F., Schumacher, K., Wolf, K. and Kurtz, A.: Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol, 12: 867, 2001
9. Whelton, A., Maurath, C. J., Verburg, K. M. and Geis, G. S.: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther, 7: 159, 2000
10. Brzozowski, T., Konturek, P. C., Konturek, S. J., Pajdo, R., Schuppan, D., Drozdowicz, D. et al: Involvement of cyclooxygenase (COX)-2 products in acceleration of ulcer healing by gastrin and hepatocyte growth factor. J Physiol Pharmacol, 51: 751, 2000
11. Howe, L. R., Subbaramaiah, K., Brown, A. M. and Dannenberg, A. J.: Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer, 8: 97, 2001
12. Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A. and Dannenberg, A. J.: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem, 274: 10911, 1999
13. Fosslien, E.: Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci, 31: 325, 2001
14. Liu, X. H., Kirschenbaum, A., Yao, S., Lee, R., Holland, J. F. and Levine, A. C.: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol, 164: 820, 2000
15. Richter, M., Weiss, M., Weinberger, I., Furstenberger, G. and Marian, B.: Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis, 22: 17, 2001
16. Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan, K. N., Masferrer, J. et al: COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 89: 2637, 2000
17. Sheng, H., Shao, J., Kirkland, S. C., Isakson, P., Coffey, R. J., Morrow, J. et al: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest, 99: 2254, 1997
18. Uefuji, K., Ichikura, T. and Mochizuki, H.: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res, 6: 135, 2000
19. Marrogi, A. J., Travis, W. D., Welsh, J. A., Khan, M. A., Rahim, H., Tazelaar, H. et al: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res, 6: 4739, 2000
20. Leahy, K. M., Koki, A. T. and Masferrer, J. L.: Role of cyclooxygenases in angiogenesis. Curr Med Chem, 7: 1163, 2000
21. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M. et al: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 60: 1306, 2000
22. Lu, X., Xie, W., Reed, D., Bradshaw, W. S. and Simmons, D. L.: Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA, 92: 7961, 1995
23. Tsujii, M. and DuBois, R. N.: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493, 1995
24. Cao, Y. and Prescott, S. M.: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol, 190: 279, 2002
25. Sheng, H., Shao, J., Morrow, J. D., Beauchamp, R. D. and DuBois, R. N.: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res, 58: 362, 1998
26. Chan, T. A., Morin, P. J., Vogelstein, B. and Kinzler, K. W.: Mechanisms underlying nonsteroidal antiinflammatory drugmediated apoptosis. Proc Natl Acad Sci USA, 95: 681, 1998
27. Yamamoto, Y., Yin, M. J., Lin, K. M. and Gaynor, R. B.: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem, 274: 27307, 1999
28. Hsu, A. L., Ching, T. T., Wang, D. S., Song, X., Rangnekar, V. M. and Chen, C. S.: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem, 275: 11397, 2000
29. Ballif, B. A., Mincek, N. V., Barratt, J. T., Wilson, M. L. and Simmons, D. L.: Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Proc Natl Acad Sci USA, 93: 5544, 1996
30. Kimura, M., Osumi, S. and Ogihara, M.: Stimulation of DNA synthesis and proliferation by prostaglandins in primary cultures of adult rat hepatocytes. Eur J Pharmacol, 404: 259, 2000
31. Marnett, L. J.: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res, 52: 5575, 1992
32. Attiga, F. A., Fernandez, P. M., Weeraratna, A. T., Manyak, M. J. and Patierno, S. R.: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res, 60: 4629, 2000
33. Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J. et al: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 164: 361, 2000
34. Quarles, L. D., Haupt, D. M., Davidai, G. and Middleton, J. P.: Prostaglandin F2 alpha-induced mitogenesis in MC3T3-E1 osteoblasts: role of protein kinase-C-mediated tyrosine phosphorylation. Endocrinology, 132: 1505, 1993
35. Tomozawa, S., Tsuno, N. H., Sunami, E., Hatano, K., Kitayama, J., Osada, T. et al: Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer, 83: 324, 2000
36. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B. et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med, 342: 1946, 2000
37. Eastham, J. A., Mire, E. and Williams, B. J.: Cyclooxygenase-2 (COX-2) expression in primary and metastatic prostate cancer. J Urol, suppl., 163: 104, abstract 453, 2000
38. Liu, X. H., Yao, S., Kirschenbaum, A. and Levine, A. C.: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down regulates bcl-2 expression in LNCaP cells. Cancer Res, 58: 4245, 1998
39. Roberts, R. O., Jacobson, D. J., Girman, C. J., Rhodes, T., Lieber, M. M. and Jacobsen, S. J.: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc, 77: 219, 2002
40. Nelson, J. E. and Harris, R. E.: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep, 7: 169, 2000
41. Norrish, A. E., Jackson, R. T. and McRae, C. U.: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer, 77: 511, 1998
42. Langman, M. J., Cheng, K. K., Gilman, E. A. and Lancashire, R. J.: Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ, 320: 1642, 2000
43. Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G. and Mukhtar, H.: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 42: 73, 2000
44. Yoshimura, R., Sano, H., Masuda, C., Kawamura, M., Tsubouchi, Y., Chargui, J. et al: Expression of cyclooxygenase-2 in prostate carcinoma. Cancer, 89: 589, 2000
45. Lee, L. M., Pan, C. C., Cheng, C. J., Chi, C. W. and Liu, T. Y.: Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res, 21: 1291, 2001
46. Uotila, P., Valve, E., Martikainen, P., Nevalainen, M., Nurmi, M. and Harkonen, P.: Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res, 29: 23, 2001
47. Madaan, S., Abel, P. D., Chaudhary, K. S., Hewitt, R., Stott, M. A., Stamp, G. W. et al: Cytoplasmic induction and overexpression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int, 86: 736, 2000
48. Kirschenbaum, A., Klausner, A. P., Lee, R., Unger, P., Yao, S., Liu, X. H. et al: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56: 671, 2000
49. Kamijo, T., Sato, T., Nagatomi, Y. and Kitamura, T.: Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol, 8: S35, 2001
50. Derksen, J. E. and Pruthi, R. S.: COX-2 inhibitors in PSA recurrent prostate cancer: a pilot study. J Urol, suppl., 167: 304, abstract 1199, 2002
51. Rao, K. V., Detrisac, C. J., Steele, V. E., Hawk, E. T., Kelloff, G. J. and McCormick, D. L.: Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis, 17: 1435, 1996
52. Grubbs, C. J, Lubet, R. A., Koki, A. T., Leahy, K. M., Masferrer, J. L., Steele, V. E. et al: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res, 60: 5599, 2000
53. Mohammed, S. I., Knapp, D. W., Bostwick, D. G., Foster, R. S., Khan, K. N., Masferrer, J. L. et al: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res, 59: 5647, 1999
54. Komhoff, M., Guan, Y., Shappell, H. W., Davis, L., Jack, G., Shyr, Y. et al: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 157: 29, 2000
55. Ristimaki, A., Nieminen, O., Saukkonen, K., Hotakainen, K., Nordling, S. and Haglund, C.: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol, 158: 849, 2001
56. Shirahama, T., Arima, J., Akiba, S. and Sakakura, C.: Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92: 188, 2001
57. Bostrom, P. J., Aaltonen, V., Soderstrom, K. O., Uotila, P. and Laato, M.: Expression of cyclooxygenase-1 and -2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesis in cultured bladder cancer cells. Pathology, 33: 469, 2001
58. Mohammed, S. I., Bennett, P. F., Craig, B. A., Glickman, N. W., Mutsaers, A. J., Snyder, P. W. et al: Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res, 62: 356, 2002
59. Gee, J. R., Lee, I.-L., Fischer, S. M., Grossman, H. B. and Sabichi, A. L.: Cyclooxygenase-2 selective inhibitors produce inhibition of growth and apoptosis in bladder cancer. J Urol, suppl., 167: 112, abstract 447, 2002
60. Belldegrun, A. and deKernion, J. B.: Renal tumors. In: Campbell's Urology, 7th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., chapt. 76, pp. 2283-2326, 1998
61. Fujioka, T., Hasegawa, M., Ogiu, K., Matsushita, Y., Sato, M. and Kubo, T.: Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma. J Urol, 155: 1775, 1996
62. Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, H., Papavassiliou, E. et al: Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Nat Acad Sci USA, 93: 10589, 1996
63. Bennett, A.: The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res, 25: 539, 1986
64. Menetrier-Caux, C., Bain, C., Favrot, M. C., Duc, A. and Blay, J. Y.: Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. Br J Cancer, 79: 119, 1999
65. Hagiwara, M., McNamara, D. B., Chen, I. L. and Fisher, J. W.: Role of endogenous prostaglandin E2 in erythropoietin production and dome formation by human renal carcinoma cells in culture. J Clin Invest, 74: 1252, 1984
66. Kleinknecht, S., Bichler, K. H. and Strohmaier, W. L.: Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma. Urol Int, 50: 121, 1993
67. Barna, B. P., Thomassen, M. J., Sergi, J., Murthy, S. and Bukowski, R. M: Immunologic changes in renal cell carcinoma patients receiving gamma interferon. Oncology, 48: 464, 1991
68. Castilla, E., Liou, L., Abrahams, N., Didonato, J. and Novick, A.: Expression of cyclooxygenase-2 (Cox-2) in renal cell carcinoma (RCC): immunohistochemical study using a high-throughput tissue microarray (TMA) and oligo microarray evaluation. J Urol, suppl., 167: 126, abstract 502, 2002
69. Chen, Q., Shinohara, N. and Koyanagi, T.: Significance of cyclooxygenase-2 expression in human renal cell carcinoma cell lines. J Urol, suppl., 167: 133, abstract 532, 2002
70. Sato, N., Mizutani, Y., Nakanishi, H., Li, Y., Nomoto, T., Nakao, M. and Miki, T.: Cytotoxic effect of a selective cyclooxygenase-2 inhibitor JTE-522 on human renal cell carcinoma cell lines. J Urol, suppl., 167: 128, abstract 512, 2002